150 related articles for article (PubMed ID: 24594506)
1. Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Kingwell E; Evans C; Zhu F; Oger J; Hashimoto S; Tremlett H
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1096-102. PubMed ID: 24594506
[TBL] [Abstract][Full Text] [Related]
2. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
Lu E; Zhu F; Zhao Y; van der Kop M; Synnes A; Dahlgren L; Sadovnick AD; Traboulsee A; Tremlett H
CNS Drugs; 2014 May; 28(5):475-82. PubMed ID: 24643915
[TBL] [Abstract][Full Text] [Related]
3. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
Kingwell E; Bajdik C; Phillips N; Zhu F; Oger J; Hashimoto S; Tremlett H
Brain; 2012 Oct; 135(Pt 10):2973-9. PubMed ID: 22730559
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: effect of beta interferon treatment on survival.
Kingwell E; Leray E; Zhu F; Petkau J; Edan G; Oger J; Tremlett H
Brain; 2019 May; 142(5):1324-1333. PubMed ID: 30883636
[TBL] [Abstract][Full Text] [Related]
6. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the safety of β-interferons in MS: A series of nested case-control studies.
de Jong HJI; Kingwell E; Shirani A; Cohen Tervaert JW; Hupperts R; Zhao Y; Zhu F; Evans C; van der Kop ML; Traboulsee A; Gustafson P; Petkau J; Marrie RA; Tremlett H;
Neurology; 2017 Jun; 88(24):2310-2320. PubMed ID: 28500224
[TBL] [Abstract][Full Text] [Related]
8. Beta-interferon exposure and onset of secondary progressive multiple sclerosis.
Zhang T; Shirani A; Zhao Y; Karim ME; Gustafson P; Petkau J; Evans C; Kingwell E; van der Kop M; Zhu F; Oger J; Tremlett H;
Eur J Neurol; 2015 Jun; 22(6):990-1000. PubMed ID: 25846809
[TBL] [Abstract][Full Text] [Related]
9. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
10. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
Lu E; Dahlgren L; Sadovnick A; Sayao A; Synnes A; Tremlett H
Mult Scler; 2012 Apr; 18(4):460-7. PubMed ID: 21914689
[TBL] [Abstract][Full Text] [Related]
11. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z
Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
[TBL] [Abstract][Full Text] [Related]
12. Liver injury associated with the beta-interferons for MS: a comparison between the three products.
Tremlett HL; Yoshida EM; Oger J
Neurology; 2004 Feb; 62(4):628-31. PubMed ID: 14981183
[TBL] [Abstract][Full Text] [Related]
13. Italian Multiple Sclerosis Database Network.
Trojano M; Paolicelli D; Lepore V; Fuiani A; Di Monte E; Pellegrini F; Russo P; Livrea P; Comi G;
Neurol Sci; 2006 Sep; 27 Suppl 5():S358-61. PubMed ID: 16998720
[TBL] [Abstract][Full Text] [Related]
14. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
15. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.
Shirani A; Zhao Y; Petkau J; Gustafson P; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
Biomed Res Int; 2015; 2015():451912. PubMed ID: 25922836
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
18. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
Pawate S; Wang L; Song Y; Sriram S
J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
[TBL] [Abstract][Full Text] [Related]
19. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
[TBL] [Abstract][Full Text] [Related]
20. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
